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Abstract 36 
 37 
Previously, we developed a 3-dimensional cell culture model of human tuberculosis (TB) and 38 
demonstrated its potential to interrogate the host-pathogen interaction (Tezera et al, 2017).  39 
Here, we use the model to investigate mechanisms whereby immune checkpoint therapy for 40 
cancer paradoxically activates TB infection.  In patients, PD-1 is expressed in Mycobacterium 41 
tuberculosis (Mtb)-infected lung tissue but absent in areas of immunopathology. In the 42 
microsphere model, PD-1 ligands are up-regulated by infection, and the PD-1/PD-L1 axis is 43 
further induced by hypoxia.  Inhibition of PD-1 signalling increases Mtb growth, and 44 
augments cytokine secretion. TNF-α is responsible for accelerated Mtb growth, and TNF-α 45 
neutralisation reverses augmented Mtb growth caused by anti-PD-1 treatment. In human TB, 46 
pulmonary TNF-α immunoreactivity is increased and circulating PD-1 expression negatively 47 
correlates with sputum TNF-α concentrations. Together, our findings demonstrate that PD-1 48 
regulates the immune response in TB, and inhibition of PD-1 accelerates Mtb growth via 49 
excessive TNF-α secretion. 50 
  51 
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Introduction 52 
 53 
Tuberculosis (TB) continues to be a global health pandemic, killing more people than any 54 
other infection (1). TB involves a complex host-pathogen interaction, with humans and 55 
Mycobacterium tuberculosis (Mtb) having undergone prolonged co-evolution (2). TB has 56 
often been thought to primarily result from loss of immune control, because approximately 57 
90% individuals infected with TB never progress to active disease, and this progression is 58 
increased in the context of immune deficiency; such as in cases of HIV infection, in infants, 59 
people with genetic deficiency of the IL-12/IFN-γ signalling pathway or after anti-TNF-α 60 
antibody treatment (3). However, an emerging concept is that an excessive immune response 61 
to Mtb may be equally harmful. Standard disease paradigms predict that immune activation 62 
resulting from the administration of checkpoint inhibitors should lead to better control of Mtb 63 
infection (4). However, counter-intuitively these agents seem to be activating TB, as 64 
evidenced by recent reports of TB developing in patients treated for malignancy with immune 65 
checkpoint inhibition, often rapidly after commencing therapy (5-15). Consistent with this 66 
emerging clinical phenomenon, programmed death (PD-1) deficient mice are highly 67 
susceptible to TB, dying more rapidly than T-cell deficient mice (16, 17).  68 
 69 
PD-1 and its ligand PD-L1 are expressed in human granulomas (10), suggesting a regulatory 70 
role at the site of disease.  TB granulomas are hypoxic (18), and PD-L1 is up-regulated by 71 
hypoxia (19), further suggesting a mechanistic link between hypoxia and the PD-1/PD-L1 72 
axis within TB lesions. In this study, we investigate the expression patterns of PD-1 and 73 
PDL-1 within TB infected human lung tissue and the relationship between PD-1 and anti-TB 74 
immunity. Next, using a human 3D cell culture model of TB (20), we show that hypoxia 75 
increases expression of PD-1 and its ligands, that PD-1 inhibition increases Mtb growth. 76 
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Surprisingly, TNF-α is primarily responsible for this effect, and TNF-α neutralisation 77 
reverses the anti-PD-1 induced phenotype. 78 
 79 
Results 80 
 81 
PD-1 is expressed in human TB granulomas but not in areas of immunopathology 82 
First, we investigated the presence and localisation of PD-1-expressing T cells in human 83 
pulmonary TB.  We hypothesised that PD-1 would be expressed by T cells in the lung of 84 
patients with TB, and at a higher frequency than in the blood.  In thirty-five patients 85 
undergoing medically indicated lung resection to treat TB or TB sequalae, PD-1 expression 86 
was measured on T cells isolated from the lung and matched blood samples, available for 23 87 
patients, by flow cytometry. Overall, PD-1 expression in homogenized lung tissue was highly 88 
variable, with a trend towards increased PD-1 in both CD4 and CD8 T-cells from the lung 89 
compared to matched blood, which reached statistical significance for CD8 T-cells (Figure 90 
1A).  Lung tissue from healthy individuals was not available for study, however, the median 91 
frequency of 11 and 14% of PD-1 +ve CD4 and CD8 T-cells observed are generally lower 92 
than recently reported for healthy human lung tissue from organ donors of approximately 93 
50% for both cell types (21).  As lung tissue is highly perfused with blood, distinguishing 94 
cells of lung or blood origin is challenging.  95 
 96 
To explore this further, we stained lung samples for canonical markers of tissue resident T-97 
cells, CD69 and CD103 (21). PD-1 expression on lung CD4 cells was predominantly 98 
restricted CD69+ve T-cells, with a smaller proportion also expressing CD103 (Fig.1B, 99 
overall frequencies Supplemental file 1), consistent with a tissue resident phenotype and in 100 
contrast to PD-1 expressing cells in blood, which are largely CD69 negative (Figure 1–figure 101 
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supplement 1). Lung CD8 T-cells were also found to predominantly express CD69 in 102 
addition to CD103, again in contrast to CD8 T-cells in circulation. Therefore, these data are 103 
consistent with expression of PD-1 on lung tissue resident T-cells in patients with active or 104 
previous pulmonary TB infection. However, TB immunopathology is highly heterogenous 105 
within the lung and these analyses do not provide information as to the localization of PD-1 106 
expression within TB lesions.  107 
 108 
To address this question, we performed immunohistochemical analysis of human lung 109 
biopsies of patients with active TB. Within stable granulomas with an intact cellular 110 
structure, PD-1 expression was present around the central macrophage core (Figure 1C-i). 111 
Both CD4 and CD8 T cells were present in the granuloma (Figure 1C-ii and -iii), and co-112 
localisation analysis demonstrated that a proportion of both T cell subtypes expressed PD-1 113 
(Figure 1C-iv), consistent with the flow cytometry data.  In contrast, in caseating granulomas 114 
with evident immunopathology, PD-1 expression was totally absent (Figure 1D-i and Figure 115 
1–figure supplement 2).  The lack of immunoreactivity was not due to lack of viable cells, as 116 
CD4 and CD8 expressing T cells were present within the same area (Figure 1D-ii and -iii).  117 
Therefore, in human granulomas, PD-1 is expressed in areas where the host-pathogen 118 
interaction appears stable but is absent in regions of immunopathology.  119 
 120 
The PD-1/ PD-L1 axis is up-regulated in the 3D microsphere model  121 
Taken together, these data from Mtb infected patients demonstrate that PD-1 is expressed by 122 
lung resident T-cells and may be required to prevent destructive lung disease. However, 123 
whether this is a causal associated remains unclear. We therefore explored the biological role 124 
of PD-1 expression in a 3-dimensional (3D) human tissue culture model. TB is a human 125 
disease characterised by a prolonged host-pathogen interaction in 3D, and is regulated by the 126 
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extracellular matrix, and previously we have previously developed a 3D cell culture model 127 
incorporating extracellular matrix to investigate TB pathogenesis (20, 22).  Here, we first 128 
studied migration of cells within the alginate-collagen matrix by performing time-lapse 129 
microscopy (Figure 2A and Video 1).  For this experiment only, UV killed Mtb was used to 130 
permit the imaging outside the containment level 3 laboratory. From 24h, progressive 131 
accumulation occurs around a central infected core, resulting in a large multicellular 132 
granuloma by 48h with dynamic cellular movement similar to the T cell mobility observed in 133 
mouse BCG granulomas (23).  134 
 135 
We next investigated whether the PD-1/PD-L1 axis was up-regulated by infection in this 3D 136 
model, and found that Mtb infection increased PD-L1 and PD-L2 gene expression at 4 days 137 
post infection (Figure 2B). Furthermore, a hypoxic environment (1% oxygen) further 138 
increased PD-L2 expression. PD-1 gene expression was not increased at 72h by Mtb infection 139 
under normoxic conditions, but was up-regulated when infected cells were incubated in 140 
hypoxia (Figure 2B). The change in expression required both infection and hypoxia, as 141 
hypoxia did not increase PD-1 or PD-L1/2 expression alone (Figure 2–figure supplement 1).   142 
We then studied PD-1/PD-L1 cellular surface expression in microspheres by flow cytometry 143 
after one week of infection. Mtb infection slightly increased PD-1 surface expression on 144 
CD4
+
 T cells in normoxia, which was augmented by hypoxia (Figure 2C). Similarly, Mtb 145 
infection increased PD-1 expression on CD8
+
 T cells, which was greater in hypoxia (Figure 146 
2D). Furthermore, on CD14
+ 
CD11b
+
 cells, PD-L1 expression was increased by infection and 147 
more so in hypoxia (Figure 2E). To investigate whether the effect of hypoxia on increased 148 
PD-1/PD-L1 expression was due to altered Mtb growth, we studied proliferation using Mtb 149 
expressing firefly luciferase and also colony counting on Middlebrook 7H11 agar. Hypoxia 150 
inhibited Mtb growth by both readouts (Figure 2F and Figure 2–figure supplement 2A). As 151 
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expected, hypoxia also increased expression of the hypoxia inducible factor, HIF-1α, in host 152 
cells (Figure 2G), but did not have a significant effect on host cell survival (Figure 2–figure 153 
supplement 2B). Therefore, the increased PD-1 and PD-L1/2 expression in hypoxia was not 154 
due to increased Mtb growth or a change in host cell viability. 155 
 156 
 157 
PD-1 pathway inhibition increases Mtb growth in the 3D model 158 
Having demonstrated that the PD-1/PD-L1 axis was up-regulated by infection in the 3D 159 
model, we investigated whether inhibition of this interaction modulated host control of Mtb. 160 
We initially studied chemical inhibitors of the PD-1/PD-L1 axis (Inhibitor 1, C29H33NO5) and 161 
found that blocking PD-1/PD-L1 binding increased Mtb growth in a dose-dependent manner 162 
(Figure 3A). This effect occurred in both normoxia and hypoxia (Figure 3–figure supplement 163 
1).  No effect of PD-1 inhibition on cell survival was noted at day 7 or day 14, utilising two 164 
different assays suited to each time point (Figure 3B and C).  Next, we studied spartalizumab, 165 
a humanised monoclonal antibody with high-affinity to PD-1 that blocks the interaction with 166 
PD-L1 and PD-L2 (24). Consistent with the chemical inhibition, PD-1 pathway inhibition 167 
using spartalizumab increased Mtb growth in normoxia in a dose-dependent manner (Figure 168 
3D). Similarly, in hypoxia spartalizumab increased Mtb growth (Figure 3E).  Microspheres 169 
must be restored to normoxia to measure Mtb luminescence, and therefore a single time point 170 
was analysed.  Anti-PD-1 antibody treatment had no significant effect on cell survival in 171 
either normoxia or hypoxia (Figure 3F). 172 
 173 
 174 
PD-1 inhibition increases secretion of multiple cytokines and growth factors 175 
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To investigate the underlying mechanism whereby PD-1 inhibition leads to increased Mtb 176 
growth, we studied secretion of cytokines, chemokines and growth factors by measuring 177 
accumulation in the media around Mtb-infected microspheres by Luminex array. Mtb 178 
infection increased secretion of numerous analytes (Figure 4–figure supplement 1), and 179 
inhibition of PD-1/PD-L1 signalling further significantly augmented secretion of twelve 180 
analytes compared to Mtb infection alone (Figure 4). A similar augmentation of analyte 181 
secretion was observed in hypoxic microspheres (Figure 4–figure supplement 2). The twelve 182 
analytes that were further increased above Mtb infection with concurrent PD-1 inhibition 183 
were IL-4, IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α, MIP-1β, RANTES, G-CSF, GM-184 
CSF and VEGF (individual concentrations, Figure 4–figure supplement 1).  Anti-PD-1 alone 185 
increased TNF-α secretion, although to a lesser effect than in combination with Mtb infection 186 
(Figure 4–figure supplement 3). 187 
 188 
Exogenous TNF-α increases Mtb growth in microspheres 189 
To establish which of these factors might be associated with increased Mtb growth, we added 190 
the significantly upregulated analytes either individually or in combination pools to 3D 191 
microspheres in normoxia at “low” (Figure 5) and “high” concentrations (Figure 5–figure 192 
supplement 1), as determined by the concentration measured in the secretion analysis. TNF-α 193 
was the dominant cytokine that increased Mtb growth, with other cytokines only having a 194 
minor effect (Figure 5A).  Chemokines (RANTES, MIP-1α and MIP-1β) and growth factors 195 
(G-CSF) had no significant effect, while GM-CSF significantly increasing Mtb growth, but 196 
the effect was smaller than for TNF-α (Figure 5B). Additionally, the only cytokine 197 
combination that had a significant effect on Mtb growth was the pro-inflammatory pool 198 
containing TNF-α, IL-6 and IL-12 (Figure 5C). The addition of Th2 cytokines, chemokines or 199 
other growth factors had no significant effect (individual growth curves at “high” 200 
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concentration, Figure 5–figure supplement 1). Furthermore, TNF-α had a progressive dose-201 
dependent effect increasing Mtb growth within microspheres (Figure 5D).  202 
 203 
To explore the effect of TNF-α further, we then generated microspheres incorporating 204 
infected PBMC with and without anti-TNF-α neutralising antibodies. Consistent with our 205 
initial observation, anti-TNF-α neutralising antibodies suppressed the TNF-mediated 206 
increased Mtb growth, with a partial reduction at each concentration studied of two different 207 
neutralising antibodies (Figure 5E and Figure 5–figure supplement 2).  Exogenous TNF-α 208 
modulated macrophage polarisation within microspheres, reducing CD80 expression at day 7 209 
(Figure 5–figure supplement 3). Therefore, we next investigated whether anti-PD-1-induced 210 
Mtb growth could be reversed by blocking TNF-α activity. Anti-PD-1 antibody treatment of 211 
infected cells again augmented Mtb growth, and this increased growth could be reversed by 212 
the incorporation of anti-TNF-α antibodies into the microspheres (Figure 5F). This confirms 213 
that an excess of TNF-α is the primary driver of increased Mtb growth caused by PD-1 214 
inhibition in the 3D model. 215 
 216 
TNF-α is highly expressed in TB granulomas and sputum TNF-α negatively correlates 217 
with circulating PD-1 expression 218 
Finally, to establish the in vivo relevance of our cell culture model findings, we performed 219 
immunohistochemical analysis of biopsies from patients with standard TB and anti-PD-1 220 
associated TB. TNF-α was expressed within TB granulomas, with greater immunoreactivity 221 
than control lung tissue at the excision margin of lung cancer (Figure 6A). Consistent with 222 
our cell culture observations, TNF-α immunostaining was extensive in a biopsy from a 223 
patient that developed pulmonary TB whilst treated with pembrolizumab, an anti-PD-1 224 
antibody (Figure 6B). Quantitative analysis of differences between standard TB and anti-PD-225 
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1 TB was not possible due to the unique nature of this clinical specimen, as TB diagnosis is 226 
usually made by bronchoalveolar lavage as opposed to percutaneous biopsy. 227 
 228 
We then analysed the association between PD-1 expression by circulating CD4
+
 and CD8
+
 T 229 
cells and sputum TNF-α concentrations in a previously reported cohort (25). Although this 230 
involved comparing PD-1 expression by circulating T cells, remote from the site of disease, 231 
with total TNF-α concentration in the sputum, we hypothesised that a reverse association 232 
would support the conclusion that PD-1 limits TNF-α secretion in patients. Consistent with 233 
this, CD4
+ 
T cell PD-1 expression negatively correlated with sputum TNF-α, with a 234 
significant negative association despite the relatively low sample numbers, which would be 235 
expected to obscure an effect (Figure 6C). 236 
 237 
 238 
 239 
Discussion 240 
Although Mtb kills more people than any other infection worldwide, an enduring enigma is 241 
that 90% of those exposed exert lifelong control of the pathogen. In seminal post-mortem 242 
studies when TB was highly prevalent in the United States, Opie showed that 30% of humans 243 
who died from other causes had viable Mtb present in the lung apices (26). Therefore, in the 244 
majority of exposed individuals, a stable relationship forms between host immune cells and 245 
Mtb without disease developing. Disseminated TB disease often develops in 246 
immunocompromised individuals, such as advanced HIV infection, newborn infants or 247 
following anti-TNF-α therapy, and this observation informs the view that TB can arise as a 248 
disease of a deficient immune response to the pathogen (3).   249 
 250 
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However, the commonest form of human TB, and the one that leads to transmission, is apical 251 
pulmonary disease (27). This occurs most frequently in young adults between the ages of 20-252 
25 with the strongest recall response to Mtb antigens, as measured by the Mantoux test (28). 253 
Therefore, these clinical observations demonstrate that infection results in a stable symbiosis 254 
between host and pathogen in the majority of individuals, and a pronounced immune 255 
response associates with the subsequent development of infectious pulmonary disease. The 256 
recently emerging clinical phenomenon of TB rapidly developing after initiating anti-PD-1 257 
immunotherapy (5-15) further reinforces that an excessive immune response in TB can be 258 
harmful. 259 
 260 
PD-1 is expressed on T cells at the site of TB disease and PD-1 expression on circulating 261 
CD4+ T cells associates with bacterial load (29). PD-1 expression is elevated in circulating 262 
CD4 T cells in TB (30) and has been proposed to limit an effective host immune response.  263 
Consequently PD-1 inhibition has been advanced as a therapeutic target to accelerate 264 
clearance of infection (4, 30-34). However, from an evolutionary perspective, PD-1 is 265 
proposed to limit immunopathology in the face of chronic antigenic stimulation (35). 266 
Therefore, it is equally plausible, and indeed perhaps more logical, that PD-1/PD-L1 pathway 267 
up-regulation in TB is a physiologically appropriate response to the persistent pathogen. We 268 
found that hypoxia further up-regulated the PD-1/PD-L1/2 axis, consistent with hypoxia 269 
increasing expression in cancer (19), and TB lesions are hypoxic both in model animals and 270 
human lesions (18, 36).  Analysis of the effect of hypoxia is complicated that both host and 271 
pathogen physiology are altered, with hypoxia causing reduced Mtb growth (37-39) but also 272 
causing diverse host physiological changes.    PD-1 may be particularly important in limiting 273 
excessive inflammation and pathology in conditions of low oxygen tension.  TB reactivation 274 
following immune checkpoint blockade, and the extreme susceptibility of PD-1 deficient 275 
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mice to Mtb infection (16, 17), would support such a regulatory role, even though it runs 276 
counter to widely advanced disease paradigms.   277 
 278 
Our work further highlights the double-edged sword of the host immune response in TB (40). 279 
TNF-α is clearly essential to an effective host immune response to TB, as disease frequently 280 
develops after treatment with anti-TNF-α antibodies (41), and TNF-α inhibits Mtb growth in 281 
zebrafish macrophages (42) and human alveolar macrophages (43).  However, excessive 282 
TNF-α is also associated with poor outcomes in TB. In human cells, an excess of TNF-α can 283 
increase Mtb growth (44, 45), consistent with our observations. In patients with active TB, 284 
TNF-α expression by Mtb-specific T cells is increased (46, 47) and TNF-α associates with 285 
more severe radiological findings (48, 49). In diverse model systems, excessive TNF-α has 286 
been shown to cause harmful inflammation (50-54), consistent with TNF-α exerting a bell-287 
shaped effect on host immunity, with either deficit or excess detrimental. Similarly, we report 288 
a deleterious effect of additional GM-CSF, in contrast to GM-CSF improving control of Mtb 289 
growth in murine macrophages (55).  This suggests that cytokine responses are highly dose 290 
and context dependent, potentially with each demonstrated non-linear responses leading to a 291 
complex matrix of what may denote the optimal cytokine profile for Mtb control.  Consistent 292 
with our findings, in the one patient that developed TB on anti-PD-1 treatment where 293 
longitudinal samples are available, there was a spike in PPD-specific TNF-α expressing cells 294 
prior to with the development of active TB (13), consistent with PD-1 acting as a regulator of 295 
TNF-α expression in TB. Taken together, these findings demonstrate a harmful effect of 296 
excessive TNF-α in TB.   297 
 298 
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We found that multiple cytokines and chemokines were increased after PD-1 inhibition, and 299 
therefore events in humans are likely to be more complex than TNF-α excess alone. The 300 
augmented inflammation may have multiple harmful effects, such as recruitment of excessive 301 
inflammatory cells and destruction of the extracellular matrix (56-58), which favour Mtb 302 
growth. In the mouse model of TB, one key role of PD-1 is to limit IFN-γ production (59), 303 
and we have shown that excess IFN-γ also accelerates Mtb growth in microspheres (20). We 304 
did not show an effect of TNF-α on cell survival, although TNF-α has been reported to 305 
increase macrophage necrosis in the zebrafish model, via a mitochondrial-lysosomal-306 
endoplasmic reticulum circuit (53, 60). The effect of PD-1 inhibition on macrophage 307 
polarisation and survival warrants further investigation, as this is likely to be one determinant 308 
of outcome (61, 62).   309 
As in all in vitro systems, the bioelectrospray model has limitations (63).  For example, it 310 
does not permit the ingress of new inflammatory cells, and therefore can only be used to 311 
investigate the early events resulting from anti-PD-1 treatment, and not the recruitment of 312 
inflammatory cells by increased chemokine secretion. In addition, although it permits longer 313 
analysis of the host-pathogen interaction than other human primary cell culture systems, the 3 314 
week standard experiment remains shorter than human infection, and so it models early 315 
events.  We have not yet characterised which cells which produce TNF-α, nor the wider 316 
phenotypic changes that result from inhibition of the PD-1 axis.  The optimal approach would 317 
be to integrate single cell RNAseq to the analysis pipeline, so the phenotype of different cells 318 
can be comprehensively analysed.  As microspheres can be readily dissolved by incubation in 319 
EDTA to release the cells, the system is suited for this technical development. 320 
 321 
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The common side effects of anti-PD-1 treatment in patients are termed immune related 322 
Adverse Events (irAEs), which are autoimmune in nature (64). We have proposed that an 323 
autoimmune process may exacerbate pathology in TB (65), and others have suggested that a 324 
loss of tolerance underlies progression to active TB (66, 67). The common theme is that an 325 
excessive response to antigens, whether host or pathogen-derived, can drive disease in TB 326 
and our findings further support this conclusion. PD-1 may act to fine tune the balance 327 
between pro- and anti-inflammatory responses necessary to control infection without causing 328 
pathology.  Notably, immune related adverse events to immune checkpoint inhibitors may be 329 
treated with anti-TNF-α antibodies (64), suggesting TNF-α may be the primary driver of both 330 
autoimmunity and TB pathology after PD-1 treatment.   331 
 332 
Our model provides the mechanistic insights into a clinical phenomenon with significant 333 
implications for future TB treatment and vaccine approaches. Simply driving a stronger 334 
immune response to Mtb seems unlikely to be beneficial, as clinical and epidemiological data 335 
suggest it may be harmful.  For example, host-directed therapies may be designed to 336 
accelerate bacterial clearance whilst concurrently reducing immunopathological effects by 337 
appropriate skewing of macrophage phenotype.  A more nuanced view considering the 338 
different immunological phases of TB is essential, differentiating events at the point of initial 339 
exposure from the late events at the apex of the lung, where excessive inflammation leads to 340 
immunopathology and transmission (68). Defining the distinction between a protective and 341 
pathological immune response in human TB remains a key unanswered question, essential to 342 
inform new interventions to control the TB pandemic. 343 
 344 
  345 
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Materials and Methods 346 
Key Resources Table 
Reagent type 
(species) or 
resource 
Designation Source or 
reference 
Identifiers Additional 
information 
Strain, strain 
background 
(Mycobacteriu
m tuberculosis) 
H37Rv  (From Ref: 
20) 
  Used at multiple of 
infection of 0.1 
Strain, strain 
background 
(Mycobacteriu
m tuberculosis) 
H37Rv 
pMV306hsp+LuxAB+G13+CD
E 
(From Ref: 
20) 
  Used at multiple of 
infection of 0.1 
Strain, strain 
background 
(Mycobacteriu
m tuberculosis) 
H37Rv pMV306hsp encoding 
the wild-type FFluc 
(From Ref: 
20) 
  Used at multiple of 
infection of 0.1 
Biological 
sample 
(Antibodies) 
        
Antibody anti-CD45-V500 Horizon 
(Clone no. HI30) 
BD 
Biosciences 
Cat.No.563792 Monoclonal mouse  
antibody 
Antibody anti-CD3 Brilliant Violet 785 
(Clone no. OKT3) 
Biolegend Cat.No.317330 Monoclonal mouse  
antibody 
Antibody anti-CD3-PE (Clone no. HIT3a) Biolegend Cat.No.300308 Monoclonal mouse  
antibody 
Antibody anti-CD4 Brilliant Ultra Violet 
496 (Clone no. SK3)  
BD 
Bioscience 
Cat.No.612937 Monoclonal mouse  
antibody 
Antibody anti-CD4-PerCP (Clone no. 
OKT4) 
Biolegend Cat.No.317432 Monoclonal mouse  
antibody 
Antibody anti-CD8 Brilliant Violet 605 
(Clone no. RPA-T8) 
Biolegend Cat.No.301040 Monoclonal mouse  
antibody 
Antibody anti-CD8-APC (Clone no. SK1) Biolegend Cat.No.344722 Monoclonal mouse  
antibody 
Antibody anti-CD103-APC (Clone no. 
Ber-ACT8) 
BD 
Biosciences 
Cat.No.563883 Monoclonal mouse  
antibody 
Antibody anti-CD69 Brilliant Ultra Violet 
395  (Clone no. FN50)  
Biolegend Cat.No.310902 Monoclonal mouse  
antibody 
Antibody anti-HLA-DR-PerCP (Clone no. 
L243) 
Biolegend Cat.No.307628 Monoclonal mouse  
antibody 
Antibody anti-CD279-BB515 (Clone no. 
EH12.1) 
BD 
Biosciences 
Cat.No.564494 Monoclonal mouse  
antibody 
Antibody anti- CD-274-BB515 (Clone no. 
MIH1) 
BD 
Biosciences 
Cat.No.564554 Monoclonal mouse  
antibody 
Antibody anti-PD-1 Brilliant Violet 421 
(Clone no.EH12.1) 
BD 
Biosciences 
 
Cat.No.562516 
Monoclonal mouse  
antibody 
Antibody anti-CD11b-APC (Clone no. 
ICRF44) 
Biolegend Cat.No.301310 Monoclonal mouse  
antibody 
Antibody anti-CD45-APC/Cy7 (Clone no. 
2D1) 
Biolegend Cat.No.368516 Monoclonal mouse  
antibody 
Antibody anti-CD14-AP/APC (Clone no. 
HCD14) 
Biolegend Cat.No.325608 Monoclonal mouse  
antibody 
Antibody anti-True-Stain Monocyte 
Blocker™  
Biolegend Cat.No.426102 Monoclonal mouse  
antibody 
Antibody anti-CD4 (Clone no. M7310) DAKO Cat.No.M7310  Monoclonal mouse  
antibody 
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Antibody anti-CD8 (Clone no. M7103)  DAKO Cat.No. M7103 Monoclonal mouse  
antibody 
Antibody anti-PD1 (Clone no. ab5287) Abcam  Cat.No.ab52587 Monoclonal mouse  
antibody 
Antibody anti-TNF-α (Clone no. ab1793) Abcam  Cat.No.ab1793 Monoclonal mouse  
antibody 
Antibody Spartalizumab  Selleckchem Cat.No.A2017  20µg/ml and 
200µg/ml, 
monoclonal , mouse 
IgG4 
Antibody IgG4  Sino 
Biologicals 
Cat.No.13505-
HNAH 
20µg/ml and 
200µg/ml,monoclona
l , mouse IgG4 
Antibody Mouse IgG1 kappa Isotype 
Control (P3.6.2.8.1), 
Thermo 
Fisher 
Scientific 
Cat.No.16-4714-
82 
50 µg/ml, mouse 
monoclonal IgG2A 
Antibody Mouse IgG1 Negative Control, 
clone Ci4 
Merck Life 
Sciences  
Cat.No.MABC00
2 
51 µg/ml, mouse 
monoclonal IgG2A 
Antibody anti-TNF-α  Thermo 
Fisher 
Scientific 
Cat.No.16-7348-
81 
52 µg/ml, mouse 
monoclonal IgG2A 
Sequence-
based reagent 
(Applied 
Biosystems 
TaqMan 
Gene 
Expression 
primers) 
GAPDH Thermo 
Fisher 
Scientific 
 
#Hs02758991_g1 
  
  β2-Microbulin  Thermo 
Fisher 
Scientific 
#Hs00608023_m
1 
  
  FNTA  Thermo 
Fisher 
Scientific 
#Hs00357739_m
1 
  
  PDCD1  Thermo 
Fisher 
Scientific 
#Hs01550088_m
1 
  
  CD274 Thermo 
Fisher 
Scientific 
#Hs00204257_m
1 
  
  PDCD1LG2  Thermo 
Fisher 
Scientific 
#Hs00228839_m
1 
  
  HIF-1α  Thermo 
Fisher 
Scientific 
#Hs00153153_m
1 
  
Commercial 
assay or kit 
CytoTox-Glo Cytotoxicity 
Assay 
Promega G9291 Commercial assay or 
kit 
  Lactate Dehydrogenase Activity 
Assay Kit 
Merck 11 644 793 001 Commercial assay or 
kit 
  Cytokine and Chemokine 35-
Plex Human ProcartaPlex™ 
Panel  
Thermo 
Fisher 
Scientific 
LHC6005M Commercial assay or 
kit 
Chemical 
compound, 
drug 
PD-1/PD-L1 Inhibitor 1  Cambridge 
Biosciences, 
UK 
 #1675201-83-8 Chemical compound 
  Recombinant Human G-CSF ImmunoTool
s 
Cat.No.11343115 1 ng/ml and 5 ng/ml 
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  Recombinant Human GM-CSF ImmunoTool
s 
Cat.No.11343125 0.25 ng/ml and 1.25 
ng/ml 
  Recombinant Human  IL-1RA / 
IL1F3 
ImmunoTool
s 
Cat.No.11344876 1.25 ng/ml and 6.25 
ng/ml  
  Recombinant Human IL-10 ImmunoTool
s 
Cat.No.11340105 0.2 ng/ml and 1 
ng/ml 
  Recombinant Human IL-6 ImmunoTool
s 
Cat.No.11340066 10.0 ng/ml and 50.0 
ng/ml 
  Recombinant Human IL-12 ImmunoTool
s 
Cat.No.11349125 0.5 ng/ml and 2.5 
ng/ml 
  Recombinant Human TNF-α ImmunoTool
s 
Cat.No.11343017 0.3 ng/ml , 1.5 
ng/ml, 7.5ng/ml and 
15ng/ml 
  Recombinant Human IL-15 ImmunoTool
s 
Cat.No.11340155 0.5ng/ml, 5ng/ml 
and 50ng/ml 
  Recombinant Human IL-17A ImmunoTool
s 
Cat.No.11340176 1 ng/ml , 10ng/ml 
and 100ng/ml 
  Recombinant Human IL-17F ImmunoTool
s 
Cat.No.11349176 1 ng/ml , 10ng/ml 
and 100ng/ml 
  Recombinant Human RANTES ImmunoTool
s 
Cat.No.11343196 0.3 ng/ml and 1.5 
ng/ml 
  Recombinant Human MIP-1α ImmunoTool
s 
Cat.No.11343206 1.5 ng/ml and 7.5 
ng/ml  
  Recombinant Human MIP-1β ImmunoTool
s 
Cat.No.11343223 1.0 ng/ml and 5 
ng/ml 
  Recombinant Human MCP ImmunoTool
s 
Cat.No.11343386 1 ng/ml , 10ng/ml 
and 100ng/ml 
Software, 
algorithm 
FlowJo  BD 
Bioscences  
version 10.6.1 Software 
  BD FACSDiva™ Software BD 
Biosciences 
  Software 
  Graphpad Prism  GraphPad 
Software 
LLC 
v7.05 Software 
  347 
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M. tuberculosis culture  348 
M. tuberculosis H37Rv (Mtb) was cultured in Middlebrook 7H9 medium (supplemented with 349 
10% ADC, 0.2% glycerol and 0.02% Tween 80) (BD Biosciences, Oxford). Bioluminescent 350 
Mtb containing luxABCDE (Mtb lux+) and Mtb expressing ffLuc (Mtb ffLuc+) were 351 
cultured with kanamycin 25μg/ml. Luminescence was measured with either GloMax® 20/20 352 
single tube luminometer (Promega,UK) or GloMax® Discover microplate reader 353 
(Promega,UK). Cultures at 1x 10
8
 CFU/ml Mtb (OD= 0.6) were used for all experiments at 354 
multiplicity of infection (MOI) of 0.1.  Live Mtb was used in all experiments apart from the 355 
time lapse microscopy, which used UV killed TB.  Mtb colony counting was performed by 356 
serial dilution on Middlebrook 7H11 Agar. Bioluminescence from the Mtb ffLuc+ was 357 
induced using D-luciferin (ThermoFisher, UK) at a concentration of 750μM in Hank’s 358 
balanced salt solution (HBSS). 359 
PBMC cell isolation from human blood  360 
For the 3D microsphere experiments, PBMC were separated from single donor leukocyte 361 
cones (National Health Service Blood and Transfusion, Southampton, UK) by density 362 
gradient centrifugation over Ficoll-Paque (GE Healthcare Life Sciences). Ethical approval for 363 
these studies was provided by the National Research Ethics Service Committee South Central 364 
- Southampton A, ref 13/SC/0043. 365 
Study participants for the correlation analysis of sputum-TNF-α with PD-1 expression on 366 
CD4
+
 and CD8
+
 T cells are the cross-sectional study individuals in a previously reported 367 
cohort (25, 69). Participants were recruited from an outpatient clinic in Khayelitsha, South 368 
Africa and were either healthy volunteers, non-TB respiratory symptomatics or recently 369 
diagnosed TB patients. Flow cytometric analysis was performed on cryopreserved PBMC 370 
isolated from whole blood as previously reported (69). The study was approved by the 371 
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University of Cape Town Human Research Ethics Committee (REF 516/2011) and conducted 372 
in accordance with the Declaration of Helsinki.  373 
Analysis of PD-1 expression in blood and lung of TB patients 374 
Lung tissue and matched PBMC were obtained from the AHRI Lung study cohort approved 375 
by the Biomedical Research Ethics Committee (BREC) of the University of Kwa-Zulu Natal, 376 
BREC reference: BE019/13. All participants underwent surgical resection to treat TB related 377 
lung complications, including haemoptysis, bronchiectasis, persistent cavitatory disease, 378 
shrunken or collapsed lung or drug-resistant infection, at the King Dinuzulu Hospital in 379 
Durban, KwaZulu- Natal and Inkosi Albert Luthuli Central Hospital (IALCH) in Durban, 380 
KwaZulu-Natal. PBMC were isolated from whole blood using standard Ficoll-Histopaque 381 
(Sigma) density gradient centrifugation by standard protocol.  382 
Lung tissues was cut into approximately 1mm
3
 pieces, washed several times with cold HBSS 383 
(Lonza) and re-suspended in 8mls of pre-warmed digestion media R10 (RPMI supplemented 384 
with 10% FCS, 2 mM L-glutamate, 100 U/ml Penstrep), containing 0.5 mg/ml collagenase D 385 
(Roche) and 40 U/ml DNaseI (Roche), and transferred to GentleMACS C-tubes (Miltenyi) 386 
for mechanical digestion according to the manufacturer’s instructions. The suspension was 387 
incubated for 30 minutes at 37
o
 C, followed by an additional mechanical digestion step and 388 
another 30-minute incubation step at 37
o
C. The final suspension was passed through a 70 μm 389 
cell strainer and washed twice in HBSS. PBMC and lung cells were phenotyped by surface 390 
staining with a near-infrared live/dead cell viability cell staining kit (Invitrogen) and a 391 
cocktail of fluorochrome conjugated antibodies: αCD45-V500 Horizon clone HI30 (BD 392 
Biosciences), CD3 Brilliant Violet 785 clone OKT3 (Biolegend), CD4 Brilliant Ultra 393 
Violet 496 clone SK3 (BD Bioscience), CD8 Brilliant Violet 605 clone RPA-T8 394 
(Biolegend), CD103-APC clone Ber-ACT8 (BD Biosciences), αCD69 Brilliant Ultra Violet 395 
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395 clone FN50 (Brilliant Horizon), PD-1 Brilliant Violet 421 clone EH12.1 (BD 396 
Biosciences). Cells were stained with 25uL of antibody cocktail in the dark for 20 minutes at 397 
room temperature followed by washing with PBS, then fixed in 2% PFA. Data was acquired 398 
using BD Aria Fusion cytometer and analyzed using FlowJo Software v.9.9 (Treestar Inc, 399 
Ashland, OR). 400 
Immunohistochemistry of paraffin-fixed tissue 401 
Immunohistochemical analysis was performed on paraffin-embedded lung tissue from 402 
patients with pulmonary TB and lung cancer that were mounted at 4µm thin onto APS coated 403 
glass slides and dried, using the following antibodies: anti-CD4 (Clone no. M7310) (DAKO), 404 
anti-CD8 (Clone no. M7103) (DAKO), anti-PD1 (Clone no. ab5287) (Abcam) and anti-TNF-405 
α (Clone no. ab1793) (Abcam). Staining was done at optimised concentrations 406 
usingrecommended buffers for each antibody.  407 
Microencapsulation of cells    408 
Microspheres were generated with an electrostatic generator (Nisco, Zurich, Switzerland) as 409 
described previously (1). Briefly, PBMC were infected overnight with Mtb in a 250cm
2
 flask, 410 
cells were detached, pelleted and mixed with 1.5% sterile alginate (Pronova UP MVG 411 
alginate, Nova Matrix, Norway) and 1mg/mL collagen (Advanced BioMatrix, USA) at a final 412 
concentration of 5 x 10
6
 cells/ml. The cell-alginate suspension was injected into the bead 413 
generator where microspheres were formed in an ionotropic gelling bath of 100mM CaCl2 in 414 
HBSS.  After washing twice with HBSS with Ca
2+
/Mg
2+
, microspheres were transferred in 415 
RPMI 1640 medium containing 10% human AB serum and incubated at 37
o
C. Microspheres 416 
were either dispensed into eppendorfs, which were then randomly allocated to different 417 
environmental conditions, or plated into a 96-well plate with conditions in triplicate 418 
according to a pre-determined template.  For experiments in hypoxia, microspheres were 419 
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incubated in 1% oxygen in Galaxy 48 R CO2 incubator (Eppendorf, UK) until analysis. 420 
Supernatants were collected at defined time points.  Time points described are days post 421 
infection. 422 
Live Cell Imaging 423 
Uninfected or UV killed Mtb infected cells suspended in alginate-collagen matrix were plated 424 
in an 8 well μ-Slide (ibidi GmbH, Germany). HBSS containing Ca2+ was used for cross-425 
linking of alginate in the extracellular matrix for 15 minutes and then replaced with RPMI 426 
medium with 10% human AB serum. Samples were imaged using an Olympus IX81 time-427 
lapse microscope with temperature of 37°C and CO2 concentration 5%. Z-stacks 200 µm in 428 
height were captured at one position in each sample every 30 minutes for 48 hours. Images 429 
were exported as tif files and opened in ImageJ.  430 
PD-1/PD-L1 Inhibition  431 
Small chemical inhibition of PD-1/PD-L1 signalling was by PD-1/PD-L1 Inhibitor 1 (CAS 432 
Registry #1675201-83-8, Cambridge Biosciences, UK), a compound that competitively 433 
blocks the interaction of PD-1 with it ligand protein PD-L1 (70). Inhibitor 1 was prepared in 434 
DMSO (Sigma-Aldrich,UK) at a concentration of 6.3mM and dissolved to a concentration of 435 
1nM, 10nM, 100nM and 1μM in complete media and added to media around microspheres on 436 
the day after encapsulation. Luminescence was monitored on specific days. For the 437 
microspheres incubated in hypoxic conditions, measurement of luminescence was repeated 438 
for every 30 minutes after the addition of luciferin until the reading plateaued, which was 439 
usually 2 hrs.  440 
In antibody inhibitory experiments, spartalizumab (Selleckchem, Germany), a humanised 441 
IgG4 anti-PD1 monoclonal antibody, was used to inhibit of PD-1/PD-L1 signalling in 442 
microspheres. Briefly, cells were infected with Mtb overnight, pelleted and then a suspension 443 
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of anti-PD1 antibodies (20 and 200μg/ml) were added and pre-incubated for 1 hour. Cells 444 
were then encapsulated within microspheres and kept for 14 days in either normoxia or 1% 445 
oxygen at 37°C and 5% CO2. Mtb growth was measured using luminescence and 446 
supernatants were taken for either cytokine or LDH measurement. An IgG4 human antibody 447 
was used at the same concentration as a control.  448 
Cell Toxicity Assays 449 
Lactate dehydrogenase (LDH) release in the supernatants collected at different time points 450 
was analysed by a colorimetric activity assay as per manufacturer’s instructions (Roche, 451 
Burgess Hill, United Kingdom). As a second assay, CytoTox-Glo Cytotoxicity Assay 452 
(Promega) was used, which measures dead-cell protease activity released from cells without 453 
membrane integrity using a luminogenic peptide substrate, the AAF-Glo™ Substrate. 454 
Luminescence from 96-well plates was analysed by GloMax Discover (Promega).  The LDH 455 
assay was suited for later time points, as this could be performed on microspheres in 456 
eppendorfs, while the CytoTox glow required analysis in 96 well plates and so was best 457 
suited to analysis in the first week. 458 
Gene Expression Analysis 459 
All the reagents were sourced from ThermoFisher Scientific (Paisley, UK). In brief, 460 
microspheres were decapsulated with 5mM EDTA, cells were pelleted and immediately lysed 461 
using TRIzol Reagent. RNA was transcribed using High Capacity cDNA Reverse 462 
Transcription kit. TaqMan® Universal master mix and primers specific for genes were 463 
GAPDH (#Hs02758991_g1), β2-Microbulin (#Hs00608023_m1), FNTA 464 
(#Hs00357739_m1), PDCD1 (#Hs01550088_m1), CD274 (#Hs00204257_m1), PDCD1LG2 465 
(#Hs00228839_m1) and HIF-1α (Hs00153153_m1) were used for qPCR according to the 466 
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manufacturer’s instructions and the comparative threshold (CT) method was employed to 467 
analyse all qPCR data. 468 
Immunophenotyping of cells from microspheres  469 
Microspheres were decapsulated with 5mM EDTA in HBSS with no Ca
2+
/Mg
2+
 at day 7 after 470 
encapsulation and 2 million cells prepared for staining in RPMI with 5% foetal bovine serum. 471 
To measure the expression of PD-1 in CD4
+
 and CD8
+
 T cells and PD-L1 expression in 472 
CD14
+
CD11b
+
 cells, the following antibody panel was used: CD3-PE (clone HIT3a, 473 
Biolegend), HLA-DR-PerCP (clone L243, Biolegend), CD4-PerCP (clone OKT4, 474 
Biolegend), CD8-APC (clone SK1, Biolegend), CD11b-APC (clone ICRF44, Biolegend), 475 
CD45-APC/Cy7 (clone 2D1, Biolegend), CD14-AP/APC (clone HCD14, Biolegend), 476 
CD279-BB515 (Clone EH12.1, BD), CD-274-BB515 (Clone MIH1, BD) and True-Stain 477 
Monocyte Blocker™ (Biolegend, USA). Gates were defined using fluorescence minus one 478 
control after exclusion of the dead cells using Live/Dead fixable stain (ThermoFisher, UK).  479 
Gating strategy is provided in Figure 5–figure supplement 4. Cells were acquired after fixing 480 
them in 2% paraformaldehyde in HBSS for 1 hour using FACSAria (Becton Dickinson, UK) 481 
and analysed by FACSDiva software (Becton Dickinson) and Flow Jo version 10 (Treestar). 482 
Cytokine supplementation 483 
Microspheres were incubated in RPMI 1640 with 10% AB serum in an opaque 12-well tissue 484 
culture plate with G-CSF, GM-CSF, IL-1RA, IL-6, IL-10, IL-12, IL-15, IL-17A, IL-17F, 485 
TNF-α, RANTES, MIP-1α, MIP-1β and MCP at two concentrations determined by the 486 
cellular experiments, at 37°C and 5% CO2. All the cytokines were purchased from 487 
ImmunoTools (Germany), suspended in RPMI with 0.1% human serum and kept at -80
O
C 488 
until use. Bacterial growth was monitored with luminescence using GloMax® Discover 489 
microplate reader (Promega,UK).  490 
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Luminex Analysis 491 
Samples were sterilised by filtration through a 0.22μM Durapore membrane (MerkMillipore). 492 
Concentrations of cytokines (ThermoFisher, UK) were determined using a Bioplex 200 493 
platform (Bio-Rad, UK) according to the manufacturer’s protocol and quantified per 494 
milligram of total protein measured by Bradford assay (Biorad).  495 
Statistical analysis 496 
All experiments were performed on a minimum of 2 occasions from separate donors as 497 
biological replicates and on each occasion with a minimum of 3 technical replicates.  Some 498 
donor-to-donor variation occurred in terms of absolute RLU, as expected in the analysis of 499 
primary human cells, but the direction of effects were always consistent.  Data presented are 500 
from a representative donor and include the mean and SEM. Analysis was performed in 501 
Graphpad Prism v7.05. Students t-test was used to compare pairs and ANOVA with Tukey’s 502 
correction for multiple comparisons for groups of 3 or more groups where it was appropriate. 503 
For the flow cytometric analysis of clinical samples, data were analysed using Mann-Whitney 504 
test for comparing pairs and Kruskal-Wallis test with Dunn’s multiple comparisons test for 3 505 
or more group.     506 
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Figure Legends  714 
Figure 1:  PD-1 is expressed in human TB granulomas. (A) Analysis of PD-1 expression by T cells 715 
in the lung and peripheral circulation of thirty-five TB patients undergoing medically indicated lung 716 
resection. PD-1 shows a trend towards higher expression by lung CD4+ (i) and is significantly higher 717 
on lung CD8+ (ii) T cells. Significance analysed by one-tailed unpaired Mann-Whitney test. (B) Flow 718 
cytometric analysis of lung parenchyma CD4+ (i) and CD8+ (ii) T cells from TB patients based on the 719 
expression of PD-1, CD69 and CD103 demonstrates increased PD-1 expression in the resident T cells 720 
in the lung parenchymal cells. Significance analysed by Kruskal-Wallis test with Dunn’s multiple 721 
comparison test. (C) Immunohistochemical staining for PD-1+, CD4+ and CD8+ expression in human 722 
lung TB granulomas. PD-1 is expressed around the central macrophage core in the same region as 723 
CD4
+
 (ii) and CD8
+
 (iii) T cells. Co-localization of PD-1 (blue), CD4
+
 (red) and CD8
+
 (yellow) using 724 
false colour of the immunostaining shows co-localisation of PD-1 with both CD4+ and CD8+ cells 725 
(purple and green respectively) (iv). Scale bar 100μm. (D) PD-1 is not expressed in caseating 726 
granulomas where immunopathology is present in human lung biopsies (i).  Six biopsies taken as part 727 
of routine clinical care were studied.  CD4+ (ii) and CD8+ (iii) expressing cells are present in the same 728 
area, and so absence of PD-1 immunoreactivity is not due to lack of viable cells.  Scale bar 200μm. 729 
Figure 2: The PD-1/ PD-L1 axis is upregulated in the 3D TB granuloma system. (A) Still images 730 
from time-lapse microscopy imaging demonstrating increasing cellular aggregation of PBMC around 731 
a focus of ultraviolet killed Mtb H37Rv in the 3D granuloma system at times 0, 12, 24 and 48h post 732 
encapsulation in the matrix.  The Z projection shows the cells contained within the designated volume 733 
in a 2D reconstruction.  Full time course in Video 1. (B) Gene expression of PD-1 and its ligands in 734 
the 3D microsphere model. RNA was extracted from live Mtb-infected PBMC and relative expression 735 
investigated by qRT-PCR at day 4 post infection. Open bars, normoxia, filled bars 1% hypoxia.  PD-736 
L1 and PD-L2 are upregulated by Mtb infection, and in 1% hypoxia PD-1 expression is increased and 737 
PD-L2 expression further augmented (n=4). Results are normalised against the housekeeping genes 738 
GAPDH, β-Microbulin and FANTA and showed similar results. β-microglobulin used for (B). 739 
*p<0.05, **p<0.01. (C-E) Surface expression of PD-1 and PD-L1.  PBMCs were decapsulated from 740 
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Mtb-infected microspheres at day 7 and surface expression of PD-1 and its ligand PD-L1 were 741 
analysed by flow cytometry. PD-1 is expressed in CD4+ (C) and CD8+ (D) T cells in PBMC from Mtb 742 
infected microspheres incubated in normoxia.  PD-1 expression was significantly upregulated in 1% 743 
hypoxia.  Representative flow cytometry plots and level of expression of PD-1 by the CD4+ and CD8+ 744 
T cell fractions are shown (n=4). (E) PD-L1 expression on CD14+CD11b+ cells within PBMC in Mtb 745 
infected microspheres is upregulated in both normoxia and 1% hypoxia at day 7 (n=4). Significance 746 
of *p<0.05. (F) Growth of Mtb H37Rv ffLux+ in microspheres in normoxia and 1% hypoxia 747 
measured at day 3, 7 and 14.  Hypoxia reduces Mtb growth. (G) Hypoxia inducible factor 1α (HIF-748 
1α) mRNA levels were increased in Mtb-infected microspheres incubated in 1% hypoxia. RNA was 749 
extracted from decapsulated microspheres and normalised to uninfected microspheres in the same 750 
environment. Results were normalised to the housekeeping genes GAPDH, β-microglobulin and 751 
FANTA to check the housekeeping gene are not affected by hypoxia. Similar results all three of the 752 
housekeeping genes. β-microglobulin used for this graph.  Significance *** p<0.001. 753 
Figure 3: PD-1 pathway inhibition increases Mtb growth. (A) Inhibition of PD-1 receptors by 754 
small chemical inhibitor 1 increases Mtb growth in a dose-response manner (1-1000nM). Inhibitor 755 
concentration 1nM (green), 10nM (purple), 100nM (blue) and 1µM (red). (B) Inhibitor 1 was not 756 
toxic to Mtb-infected PBMC, analysed by CytoTox-Glo assay (Day 7). (C) Cellular toxicity was no 757 
different at day 14 as analysed by LDH release. Concentration 1 and 1000nM were analysed for 758 
toxicity.  (D) Spartalizumab, a therapeutic monoclonal anti-PD-1 antibody, progressively increased 759 
Mtb growth in microspheres in normoxia in a dose-dependent manner.  (E) Spartalizumab also 760 
increased Mtb growth in hypoxia. Media (black), isotype (blue), spartalizumab 20µg/ml (green) and 761 
200µg/ml (red). (F) The anti-PD-1 antibody had no effect on cell survival in microspheres in 762 
normoxia (clear bars) and 1% hypoxia (filled bars). Cytotoxity is determined by measuring LDH 763 
release at day 14 and normalized by the control. ****p<0.0001. 764 
Figure 4: PD-1 inhibition increases secretion of multiple cytokines and growth factors. PD-1/PD-765 
L1 signalling was inhibited by Spartalizumab, a humanized IgG4 anti-PD1 monoclonal antibody, in 766 
Mtb-infected microspheres at 20 and 200µ/ml in normoxia. Supernatants were collected at day 14 and 767 
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accumulation of cytokines and growth factors was analysed by Luminex 35-multiplex assay. 768 
Concentrations were normalized to secretion by Mtb infected microspheres to demonstrate relative 769 
fold change, and individual concentrations are shown in Supplementary figure 6. The experiment was 770 
performed twice with three replicates.   Red font:  ** p<0.001 for Spartalizumab versus isotype 771 
control.  772 
Figure 5: Addition of TNF-α increases Mtb growth in microspheres in normoxia. Recombinant 773 
human G-CSF, GM-CSF, IL-4, IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α, MIP-1β or RANTES 774 
were added either individually (A and B) or in combination pools (C) to Mtb-infected microspheres at 775 
“low” concentrations, defined as that measured in media around spheres after anti-PD-1 treatment. 776 
Recombinant human TNF-α increases growth of Mtb, whilst other pro-inflammatory cytokines did 777 
not (A).  GM-CSF has a lesser growth-promoting effect (B).   The only combination pool that 778 
increased Mtb growth was the pro-inflammatory cytokine pool, containing TNF-α (C). (D) TNF-α 779 
results in a dose-dependent increase in the Mtb growth over time. (E) Anti-TNF-α neutralising 780 
antibodies partially suppress the increased Mtb growth caused by TNF-α augmentation. Anti-TNF-α 781 
from Thermo Fisher Scientific. (F) Anti-PD1 antibody incorporation within microspheres increases of 782 
Mtb growth at day 7, and this effect is reversed by concurrent anti-TNF-α neutralising antibodies 783 
within microspheres. The constituent of the cytokine pools are: Growth factor pool (GF: GM-CSF and 784 
G-CSF), Anti-Inflammatory cytokine pool (Anti-Inf: IL-10 and IL-1RA), Pro-Inflammatory cytokine 785 
pool (Pro-Inf: TNF-α, IL-6 and IL-12) and Chemokine pool (Chemo: RANTES, MIP-1α, MIP-1β).    786 
Figure 6: TNF-α is expressed in human TB granulomas and sputum TNF-α concentrations 787 
negatively correlate with circulating PD-1 expression. (A) TNF-α is expressed within human lung 788 
TB granulomas, with greater immunoreactivity than control lung tissue at the excision margin of lung 789 
cancer (i & ii). Quantification of TNF-α immunostaining (n=5) in TB cases was significantly higher 790 
than controls (n=5) (iii).   (B) TNF-α immunostaining was extensive in the lung granuloma of a 791 
patient that developed TB whilst treated with pembrolizumab, a humanized anti-PD-1 antibody (n=1). 792 
(C) CD4+ T cell PD-1 expression on circulating PBMC negatively correlates with sputum TNF-α 793 
concentration in a separate cohort where paired sputum and PBMCs samples are available.  Green 794 
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dots, healthy controls; Black TB cases; Orange respiratory symptomatics.  Analysis by Spearman’s 795 
correlation analysis gave r-value of -0.341 with p=0.0484  796 
 797 
Figure supplement legends 798 
 799 
Figure 1–figure supplement 1: PD-1 expression on peripheral CD4+ and CD8+ T-cells is 800 
predominantly on CD103- and CD69-negative cells. Significance was analyzed by one-tailed 801 
unpaired Mann-Whitney test. 802 
Figure 1–figure supplement 2: PD-1 expressing cells are absent in the immediate region surrounding 803 
caseous necrosis in human TB granulomas.  Images from four different clinical samples are presented. 804 
Scale bar 100μm. 805 
Figure 2–figure supplement 1: Hypoxia alone has no significant effect on expression of the PD-806 
1/PDL-1/2 axis. Gene expression PD-1 and its ligands in uninfected cells was compared between 807 
normoxic and hypoxic conditions in the microsphere model. RNA was extracted from uninfected 808 
PBMCs and relative expression investigated by qRT-PCR at day 4. Open bars PD-1, filled bars PD-809 
L1 and black bars PD-L2 respectively.  Results were normalised against the housekeeping genes 810 
GAPDH, β-Microbulin and FANTA and showed similar results.  No significant changes in gene 811 
expression were noted in uninfected microspheres.  β-microglobulin used for the analysis presented. 812 
Figure 2–figure supplement 2:  (A) Mtb H37Rv ffluc+ growth in 1% hypoxia. Microspheres were 813 
decapsulated in a media containing 5mM EDTA and 0.1% saponin at day 14.  The lysate was 814 
centrifuged, re-suspended in 1ml PBS, serially diluted and grown in Middlebrook 7H11 media for 3 815 
weeks before colony counting.  (B)  Host cell viability using 3D CytoxGlo viability assay (Promega) 816 
shows no significant difference between normoxia (open bars) and hypoxia (filled bars) at day 4 and 817 
day 7.   818 
39 
 
Figure 3–figure supplement 1: Small chemical inhibition of PD-1/PD-L1 interaction in 1% hypoxia 819 
measured at day 14 shows a dose-dependent increase in Mtb growth with PD-1 inhibition. *** 820 
p<0.0001 with one-way ANOVA with Dunnett’s multiple comparison test. 821 
Figure 4–figure supplement 1: Cytokine accumulation around microspheres after inhibition of PD-822 
1/PD-L1 signalling with Spartalizumab, a humanized IgG4 anti-PD1 monoclonal antibody at 20 and 823 
200µg/ml in normoxia (N) and 1% hypoxia (H). Supernatants were collected at day 14 and a Luminex 824 
35-multiplex assay was performed. The experiment was performed twice with three replicates.  825 
Concentrations are in pg/ml. Labels in red correspond to significantly raised cytokine values. Red 826 
font:  Significance **p<0.001.  827 
Figure 4–figure supplement 2:  PD-1 inhibition increases secretion of multiple cytokines and growth 828 
factors in 1% hypoxia.   Supernatants were collected at day 14 and accumulation of cytokines and 829 
growth factors was analysed by Luminex 35-multiplex assay. Concentrations were normalized to 830 
secretion by Mtb infected microspheres to demonstrate relative fold change, and individual 831 
concentrations are shown in Supplementary figure 5. The experiment was performed twice with three 832 
replicates.   Red font:  ** p<0.001 for Spartalizumab versus Isotype control. 833 
Figure 4–figure supplement 3: Spartalizumab induces TNF-α secretion in uninfected and infected 834 
microspheres, which is neutralised by anti-TNF-α.   PBMCs which were uninfected or infected with 835 
Mtb were encapsulated in alginate-collagen matrix after pre- incubation in Spartalizumab at 836 
200μg/ml.  The supernatant was collected to measure TNF-α secretion at day 7.  (A) Spartalizumab 837 
induces TNF-α secretion in uninfected cells above background, which is accentuated with Mtb 838 
infection. (B)  Anti-PD-1 antibody increases TNF-α secretion from Mtb infected cells above isotype, 839 
and the detectable levels are suppressed by anti-TNF antibody (50μg/ml).   840 
Figure 5–figure supplement 1: Individual Mtb growth curves at “high” cytokine concentration, five 841 
times the concentration measured in media after anti-PD-1 treatment.  Human recombinant G-CSF, 842 
GM-CSF, IL-4, IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α, MIP-1β and RANTES were added to 843 
microspheres either individually or in combination pools to microspheres at 5 times the concentrations 844 
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in Figure 5, determined by the concentration measured in the media around the microspheres. TNF-α 845 
increases Mtb growth in microspheres alone and in the pro-inflammatory pool. 846 
Figure 5–figure supplement 2: Anti-TNF-α neutralizing antibodies supress the Mtb growth 847 
following TNF-α from a different source (Anti-TNF-α from Sigma-Aldrich, UK). 848 
Figure 5–figure supplement 3: TNF-α skews polarization of monocytes to macrophages with lower 849 
CD80 expression. PBMCs were infected with Mtb H37Rv at MOI of 0.1 and encapsulated in alginate-850 
collagen microspheres after overnight incubation. Microspheres were then incubated in complete 851 
RPMI (with L-Glutamine and 10% human serum) with TNF-α 7.5ng/ml. Uninfected PBMCs were 852 
encapsulated and treated similarly as a comparator for TNF-α stimulation. At day 7, the microspheres 853 
were decapsulated in 0.5mM EDTA solution at pH of 7.2. Double staining with CD14 and CD11b 854 
defined macrophages, which were classified by CD80 and CD163 expression. (A) Histogram showing 855 
expression of CD163 and CD80 where there was significant decrease in CD80 expression as shown if 856 
Figure (B). TNF suppressed the relative geometric mean of CD80, but did not affect CD163 857 
expression. This experiment was performed in 4 separate donors. 858 
Figure 5–figure supplement 4: Hierarchical gating strategy used to identify lymphocyte and 859 
monocytic populations from decapsulated microspheres containing human peripheral blood 860 
monocular cells. Single cells were decapsulated from microspheres in 5mM EDTA, washed and 861 
processed for flow cytometry.  First doublets were excluded from live cells, then cells were gated as 862 
CD3+ and CD3- . Subsequently, lymphocytes were further classified into CD4+ and CD8+, which are 863 
sub-categorized based on PD-1 staining. Double staining with both CD14 and CD11b defined 864 
macrophages, which were further analysed for PD-L1, CD80 and CD163 surface expression. All the 865 
antibodies and clone number are listed in the text and the key resources table.     866 
 867 
Supplementary file 1:  PD-1 expressing cells for each subset expressed as percentage of live CD45+ 868 
cells, with range in parentheses.   869 
 870 
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Video 1: Cell migration over 48 hours around a central cluster of  871 
macrophages infected with UV-killed Mtb within a 3D alginate-collagen matrix.  Migration is seen in 872 
the first 24 hours, without aggregation, and then progressive granuloma formation occurs. 873 
 874 
 875 
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Figure 1–figure supplement 1: PD-1 expression on peripheral CD4+ and CD8+ T-cells is 1 
predominantly on CD103- and CD69-negative cells. Significance was analyzed by one-tailed unpaired 2 
Mann-Whitney test. 3 
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Figure 1–figure supplement 2: PD-1 expressing cells are absent in the immediate region surrounding 1 
caseous necrosis in human TB granulomas.  Images from four different clinical samples are presented. 2 
Scale bar 100μm. 3 
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Figure 2–figure supplement 1: Hypoxia alone has no significant effect on expression of the PD-
1/PDL-1/2 axis. Gene expression PD-1 and its ligands in uninfected cells was compared between 
normoxic and hypoxic conditions in the microsphere model. RNA was extracted from uninfected 
PBMCs and relative expression investigated by qRT-PCR at day 4. Open bars PD-1, filled bars PD-L1 
and black bars PD-L2 respectively.  Results were normalised against the housekeeping genes GAPDH, 
β-Microbulin and FANTA and showed similar results.  No significant changes in gene expression were 
noted in uninfected microspheres.  β-microglobulin used for the analysis presented. 
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Figure 2–figure supplement 2A:  (A) Mtb H37Rv ffluc+ growth in 1% hypoxia. Microspheres were 1 
decapsulated in a media containing 5mM EDTA and 0.1% saponin at day 14.  The lysate was 2 
centrifuged, re-suspended in 1ml PBS, serially diluted and grown in Middlebrook 7H11 media for 3 3 
weeks before colony counting.  (B)  Host cell viability using 3D CytoxGlo viability assay (Promega) 4 
shows no significant difference between normoxia (open bars) and hypoxia (filled bars) at day 4 and 5 
day 7.   6 
Mt
b
Inh
1-1
0
Inh
1-1
00
Inh
1-1
00
0
0
1×104
2×104
3×104
4×104
M
tb
 G
ro
w
th
 (R
LU
)
***
Figure 3–figure supplement 1: Small chemical inhibition of PD-1/PD-L1 interaction in 1% hypoxia 1 
measured at day 14 shows a dose-dependent increase in Mtb growth with PD-1 inhibition. *** p<0.0001 2 
with one-way ANOVA with Dunnett’s multiple comparison test. 3 
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Figure 4-figure supplement 1 (legend overleaf)
Figure 4–figure supplement 1: Cytokine accumulation around microspheres after inhibition of PD-
1/PD-L1 signalling with Spartalizumab, a humanized IgG4 anti-PD1 monoclonal antibody at 20 and 
200µg/ml in normoxia (N) and 1% hypoxia (H). Supernatants were collected at day 14 and a Luminex 
35-multiplex assay was performed. The experiment was performed twice with three replicates.  
Concentrations are in pg/ml. Labels in red correspond to significantly raised cytokine values. Red 
font:  Significance **p<0.001.  
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Figure 4–figure supplement 2:  PD-1 inhibition increases secretion of multiple cytokines and growth 
factors in 1% hypoxia.   Supernatants were collected at day 14 and accumulation of cytokines and 
growth factors was analysed by Luminex 35-multiplex assay. Concentrations were normalized to 
secretion by Mtb infected microspheres to demonstrate relative fold change, and individual 
concentrations are shown in Supplementary figure 5. The experiment was performed twice with three 
replicates.   Red font:  ** p<0.001 for Spartalizumab versus Isotype control. 
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Figure 4–figure supplement 3: Spartalizumab induces TNF-α secretion in uninfected and infected 1 
microspheres, which is neutralised by anti-TNF-α.   PBMCs which were uninfected or infected with 2 
Mtb were encapsulated in alginate-collagen matrix after pre- incubation in Spartalizumab at 200μg/ml.  3 
The supernatant was collected to measure TNF-α secretion at day 7.  (A) Spartalizumab induces TNF-4 
α secretion in uninfected cells above background, which is accentuated with Mtb infection. (B)  Anti-5 
PD-1 antibody increases TNF-α secretion from Mtb infected cells above isotype, and the detectable 6 
levels are suppressed by anti-TNF antibody (50μg/ml).   7 
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Figure 5–figure supplement 1: Individual  
Mtb growth curves at “high” cytokine  
concentration, five times the concentration 
measured in media after anti-PD-1 treatment.  
Human recombinant G-CSF, GM-CSF, IL-4,  
IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α,  
MIP-1β and RANTES were added to 
microspheres either individually or in  
combination pools to microspheres at 5 times  
the concentrations in Figure 5, determined by  
the concentration measured in the media 
around the microspheres. TNF-α increases 
Mtb growth in microspheres alone and in the  
pro-inflammatory pool.  
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Figure 5–figure supplement 2: Anti-TNF-α neutralizing antibodies supress the Mtb growth following 
TNF-α from a different source (Anti-TNF-α from Sigma-Aldrich, UK). 
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Figure 5–figure supplement 3: TNF-α skews polarization of monocytes to macrophages with lower 
CD80 expression. PBMCs were infected with Mtb H37Rv at MOI of 0.1 and encapsulated in alginate-
collagen microspheres after overnight incubation. Microspheres were then incubated in complete RPMI 
(with L-Glutamine and 10% human serum) with TNF-α 7.5ng/ml. Uninfected PBMCs were 
encapsulated and treated similarly as a comparator for TNF-α stimulation. At day 7, the microspheres 
were decapsulated in 0.5mM EDTA solution at pH of 7.2. Double staining with CD14 and CD11b 
defined macrophages, which were classified by CD80 and CD163 expression. (A) Histogram showing 
expression of CD163 and CD80 where there was significant decrease in CD80 expression as shown if 
Figure (B). TNF suppressed the relative geometric mean of CD80, but did not affect CD163 expression. 
This experiment was performed in 4 separate donors. 
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Figure 5–figure supplement 4: Hierarchical gating strategy used to identify lymphocyte and 1 
monocytic populations from decapsulated microspheres containing human peripheral blood monocular 2 
cells. Single cells were decapsulated from microspheres in 5mM EDTA, washed and processed for flow 3 
cytometry.  First doublets were excluded from live cells, then cells were gated as CD3+ and CD3- . 4 
Subsequently, lymphocytes were further classified into CD4+ and CD8+, which are sub-categorized 5 
based on PD-1 staining. Double staining with both CD14 and CD11b defined macrophages, which were 6 
further analysed for PD-L1, CD80 and CD163 surface expression. All the antibodies and clone number 7 
are listed in the text and the key resources table.     8 
